PDSB · XBRL financial data

PDS Biotechnology financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PDSB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	7,924	11,255	29,431	27,763	22,566	19,026
General and administrative	6,962	10,185	12,241	15,282	13,756	12,518
Total operating expenses	14,902	21,439	41,672	43,045	36,321	31,544
Operating income (loss)	(14,902)	(21,439)	(41,672)	(43,045)	(36,321)	(31,544)
Interest income	55	4	935	2,903	2,515	1,217
Interest expense	0	0	1,317	4,206	4,673	5,339
Income tax expense (benefit)	0	(4,516)	(1,199)	(1,406)	(869)	(1,170)
Net income (loss)	(14,847)	(16,918)	(40,855)	(42,942)	(37,610)	(34,496)
Earnings per share, basic USD per share	(0.89)	(0.66)	(1.43)	(1.39)	(1.03)	(0.74)
Earnings per share, diluted USD per share	(0.89)	(0.66)	(1.43)	(1.39)	(1.03)	(0.74)
Weighted average shares, basic thousands of shares	16,745	25,597	28,599	30,952	36,453	46,384
Weighted average shares, diluted thousands of shares	16,745	25,597	28,599	30,952	36,453	46,384

Fiscal years (PDSB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	28,840	65,243	73,820	56,561	41,690	26,712
Prepaid and other current assets	1,498	1,598	2,660	2,495	3,365	1,542
Total current assets	30,337	66,840	76,480	59,055	45,054	28,254
Property and equipment, net	5	0	0	134	142	120
Right-of-use asset	548	358	153	0	—	—
Total assets	30,890	67,198	77,008	59,390	45,359	30,494
Accounts payable	1,415	1,309	1,219	6,983	1,685	3,574
Accrued liabilities	1,735	2,188	8,314	2,425	2,841	742
Total current liabilities	3,270	3,756	9,821	13,630	17,087	9,483
Lease liability, non-current	490	231	0	0	—	—
Total liabilities	3,761	3,987	33,006	33,259	26,354	21,242
Accumulated deficit	(43,785)	(60,704)	(101,558)	(144,501)	(182,111)	(216,607)
Total stockholders' equity	27,130	63,210	44,002	26,131	19,005	9,252
Total liabilities and equity	30,890	67,198	77,008	59,390	45,359	30,494
Common shares outstanding (cover page) thousands of shares	22,262	28,449	30,724	36,679	45,396	55,816

Fiscal years (PDSB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(14,847)	(16,918)	(40,855)	(42,942)	(37,610)	(34,496)
Stock-based compensation	432	4,074	5,196	7,614	6,848	4,107
Net cash from operating activities	(13,149)	(12,486)	(25,710)	(33,636)	(35,030)	(27,752)
Purchases of property and equipment	—	—	—	0	29	0
Net cash from investing activities	0	—	—	0	(29)	0
Proceeds from issuing common stock	29,757	48,545	9,856	16,127	22,595	9,709
Net cash from financing activities	29,827	48,889	34,287	16,376	20,188	12,774

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.